Haemonetics Co. (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Haemonetics Co. (NYSE:HAE) have received an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $107.88.

A number of research firms recently commented on HAE. Bank of America began coverage on shares of Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price target on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a report on Friday, November 8th. CL King started coverage on shares of Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 target price on the stock. BTIG Research started coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $112.00 target price on shares of Haemonetics in a report on Friday, November 15th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HAE. CANADA LIFE ASSURANCE Co grew its position in Haemonetics by 13.2% in the first quarter. CANADA LIFE ASSURANCE Co now owns 50,728 shares of the medical instruments supplier’s stock worth $4,330,000 after acquiring an additional 5,933 shares in the last quarter. PEAK6 Investments LLC purchased a new position in Haemonetics in the first quarter worth $452,000. Price T Rowe Associates Inc. MD grew its position in Haemonetics by 38.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock worth $48,006,000 after acquiring an additional 156,665 shares in the last quarter. Janus Henderson Group PLC grew its position in Haemonetics by 26.8% in the first quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier’s stock worth $2,536,000 after acquiring an additional 6,287 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in Haemonetics by 25.6% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 53,651 shares of the medical instruments supplier’s stock worth $4,579,000 after acquiring an additional 10,930 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

Shares of NYSE HAE opened at $88.49 on Tuesday. Haemonetics has a twelve month low of $70.25 and a twelve month high of $97.97. The stock’s 50 day moving average price is $78.99 and its 200-day moving average price is $82.29. The company has a market capitalization of $4.44 billion, a PE ratio of 36.72, a PEG ratio of 1.33 and a beta of 0.32. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.99 EPS. On average, equities analysts anticipate that Haemonetics will post 4.59 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.